Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% above its 5-year average of -0.16, around the middle of its 5-year range (-502.31–759.74).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -0.41.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-0.41
DEBT TO EQUITY RATIO AVG 3Y
-0.23
DEBT TO EQUITY RATIO AVG 5Y
-0.16
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 582 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aspire Biopharma Holdings, Inc.
Market Cap
$1.03M
Debt to Equity Ratio
0.00
TTM Avg
-0.41
3Y Avg
-0.23
5Y Avg
-0.16
Market Cap
$1.07M
Debt to Equity Ratio
0.14
TTM Avg
0.76
3Y Avg
0.50
5Y Avg
0.30
Market Cap
$1.10M
Debt to Equity Ratio
0.13
TTM Avg
0.30
3Y Avg
0.57
5Y Avg
0.57
Market Cap
$1.24M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$870069.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$862314.00
Debt to Equity Ratio
N/A
TTM Avg
0.01
3Y Avg
0.08
5Y Avg
0.06
Market Cap
$856468.00
Debt to Equity Ratio
0.00
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$832531.00
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.03M | 0.00 | -0.41 | -0.23 | -0.16 |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | 0.14 | 0.76 | 0.50 | 0.30 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | 0.13 | 0.30 | 0.57 | 0.57 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.24M | N/A | 0.05 | 0.05 | 0.05 |
| IM Cannabis Corp. (IMCC)vs › | $1.16M | N/A | 2.19 | 1.26 | 0.86 |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| GlucoTrack, Inc. (GCTK)vs › | $862314.00 | N/A | 0.01 | 0.08 | 0.06 |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | 0.00 | 0.07 | 0.05 | 0.04 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $832531.00 | 0.01 | 0.03 | 0.06 | 0.04 |
| Genprex, Inc. (GNPX)vs › | $1.36M | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
0.00
Current Ratio
7.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.39 |
| 2025-12-31 | -0.81 |
| 2025-09-30 | -0.75 |
| 2025-06-30 | -0.88 |
| 2025-03-31 | -0.97 |
| 2024-12-31 | -0.82 |
| 2024-09-30 | 4.83 |
| 2024-06-30 | 1.01 |
| 2024-03-31 | 0.11 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | -502.31 |
| 2021-09-30 | 759.74 |
| 2021-06-30 | 1.98 |
| 2021-03-31 | 1.67 |
